# PRNP D178N Research Report

**Protein:** PRNP D178N
**Variant:** D178N
**UniProt ID:** P04156
**Disease Association:** Prion disease (CJD, FFI, GSS)
**Report Generated:** 2026-05-26 03:48 UTC
**AlphaFold Confidence (pLDDT):** 62.8%
**Structure Folded:** 2026-05-19

---

## Structure Summary

# Analysis of D178N Prion Protein Structure (AlphaFold Prediction)

## TLDR

This computational model shows the D178N mutation in prion protein, which causes familial prion disease (specifically familial Creutzfeldt-Jakob disease and fatal familial insomnia). The predicted structure appears reasonably well-defined in most regions, though some flexible loops show lower confidence, which is typical for this protein's naturally disordered N-terminal domain.

---

## Detailed Structural Analysis

### Structural Confidence (pLDDT Interpretation)

The B-factors (reported as pLDDT scores) range from **26–71**, indicating variable confidence across the structure:

- **High confidence (pLDDT >60)**: Early N-terminal residues (Met1–Leu11, Val13–Ala14) and scattered mid-region elements show strong predicted reliability, suggesting these form stable secondary structures.
- **Moderate confidence (pLDDT 45–60)**: Most of the central and later regions (residues 20–67) display intermediate confidence, typical of helical or loop regions that are intrinsically dynamic.
- **Lower confidence (pLDDT <45)**: Several flexible loop regions (particularly around Gly29–Gly30, Gly45–Gly46, Gly53–Gly56) show reduced confidence, consistent with the known flexibility of prion protein's unstructured N-terminal domain.

This pattern is **expected and biologically reasonable**—prion protein naturally contains a flexible, unstructured N-terminus that becomes partially ordered upon conversion to the pathogenic PrP^Sc form.

---

### Key Structural Features

**Secondary Structure Elements:**
- The sequence exhibits multiple turn-promoting residues (Gly, Pro) clustered at positions 5, 20, 28–30, 44–46, 53–56, characteristic of loops or coil regions.
- Several hydrophobic residues (Leu, Val, Phe, Trp) form a potential hydrophobic core, important for protein stability.
- Two disulfide-forming cysteines are present (Cys6, Cys22), though their bonding state cannot be definitively determined from coordinates alone. These are functionally important in native prion protein.

**Notable Residues & Domains:**
- **N-terminal Region (Met1–Lys27)**: Relatively unstructured; this is the "flexible domain" that increases accessibility to proteolytic cleavage and may facilitate misfolding.
- **Cys6 & Cys22**: These cysteines normally form a disulfide bond critical for structural integrity; disruption of this bond in misfolded PrP^Sc is relevant to disease pathogenesis.
- **Tryptophan-rich regions** (Trp7, Trp16, Trp31, Trp57, Trp65): These aromatic residues often participate in hydrophobic packing and may be involved in protein aggregation pathways.

---

### D178N Mutation: Disease Relevance

**The D178N substitution** (aspartic acid → asparagine at position 178) is located in the **C-terminal structured region** of prion protein and is one of the most common pathogenic mutations causing:

1. **Familial CJD (fCJD)**: The dominant presentation when paired with the **129-valine polymorphism** (Met129 allele typically associates with fCJD; Val129 with FFI).
2. **Fatal Familial Insomnia (FFI)**: When linked to the methionine-129 polymorphism—characterized by intractable insomnia, autonomic dysfunction, and rapid neurodegeneration.
3. **Familial Gerstmann-Sträussler-Scheinker Syndrome (GSS)**: In some genetic backgrounds.

**Structural Consequences of D178N:**
- **Loss of negative charge**: Aspartate (Asp, D) is a negatively charged, hydrophilic residue; asparagine (Asn, N) is polar but uncharged. This reduces electrostatic stabilization in the local region.
- **Altered hydrogen bonding**: Asparagine can form backbone hydrogen bonds but lacks the extended electrostatic interactions of aspartate, potentially destabilizing local structure or facilitating misfolding.
- **Increased aggregation propensity**: The reduced charge likely increases the protein's propensity to self-associate and adopt the pathogenic β-rich PrP^Sc conformation.
- **Location significance**: Position 178 is close to the structured C-terminal domain (residues ~120–230), making this mutation particularly disruptive to the native fold.

---

### Biological Relevance to Prion Disease Pathogenesis

**Why D178N Causes Disease:**

1. **Destabilized native structure**: The mutation weakens the stability of normal α-helical PrP^C, lowering the energy barrier for conversion to the misfolded PrP^Sc form.

2. **Seeding effect**: Even small amounts of misfolded D178N-PrP can seed conversion of wild-type prion protein, explaining autosomal dominant inheritance and variable penetrance.

3. **Prion propagation**: The altered structure favors formation and propagation of misfolded conformers that resist protease digestion (a hallmark of PrP^Sc).

4. **Phenotypic heterogeneity**: The specific disease manifestation (CJD vs. FFI vs. GSS) depends on:
   - The genetic background at codon 129 (Met vs. Val)
   - The specific misfolded PrP^Sc conformer that propagates (strain-like properties)
   - Environmental and epigenetic factors

---

### Notable Regions in This Structure

| Region | Residues | Confidence | Features |
|--------|----------|-----------|----------|
| **N-terminal flexibility** | Met1–Gly20 | 51–61 (moderate) | Unstructured domain; vulnerable to cleavage; increased in prediction |
| **Disulfide region** | Cys6, Cys22 | 61–54 | Functionally critical for native stability |
| **Central loops** | Gly29–Gly30, Gly45–Gly56 | 37–43

---

## Clinical Data

### ClinVar

Not found in ClinVar.

### gnomAD Population Data
- **Allele Frequency:** 6.84e-07
- **Allele Count:** 1
- **Allele Number:** 1461876

---

## Open Targets Disease Associations

| Disease | Score | Data Sources |
|---------|-------|--------------|
| Gerstmann-Straussler-Scheinker syndrome | 0.825 | literature, animal_model, genetic_association, genetic_literature |
| Creutzfeldt Jacob Disease | 0.785 | literature, animal_model, genetic_association, genetic_literature |
| Huntington disease-like 1 | 0.759 | literature, animal_model, genetic_association, genetic_literature |
| fatal familial insomnia | 0.720 | literature, genetic_association, genetic_literature |
| inherited Creutzfeldt-Jakob disease | 0.717 | literature, animal_model, genetic_association, genetic_literature |
| prion disease | 0.666 | literature, genetic_association, genetic_literature |
| cerebral amyloid angiopathy | 0.649 | literature, genetic_association, genetic_literature |
| dementia | 0.510 | literature, genetic_literature |
| neurodegenerative disease | 0.507 | literature, affected_pathway |
| genetic disorder | 0.491 | literature, genetic_association |

*...and 986 more associations*

---

## AI Research Brief

# Research Brief: PRNP D178N Variant

## Pathogenic Mechanisms

The PRNP D178N variant represents a critical mutation in the prion protein gene that drives pathogenesis through altered protein conformation and function. This substitution of aspartic acid to asparagine at position 178 disrupts the normal cellular prion protein (PrP^C) structure, promoting conversion to the pathogenic scrapie form (PrP^Sc). The variant's pathogenic mechanism is uniquely influenced by a polymorphism at codon 129, where the methionine/valine status determines distinct clinical phenotypes. The mutation occurs within a functionally critical region of the protein that normally participates in copper ion binding and cellular stress responses. Given PRNP's known molecular functions including amyloid-beta binding and aspartic-type endopeptidase inhibitor activity, the D178N substitution likely compromises these protective mechanisms while simultaneously enhancing aberrant protein-protein interactions with known interactors such as APP and HTT, potentially accelerating neurotoxic cascades.

## Clinical Significance

The D178N variant demonstrates complete penetrance and causes two distinct autosomal dominant prion diseases: Fatal Familial Insomnia (FFI) when coupled with methionine at codon 129, or familial Creutzfeldt-Jakob disease (fCJD) with valine at this position. This genotype-phenotype correlation makes D178N clinically significant as a definitive pathogenic variant requiring careful genetic counseling and codon 129 haplotype determination. FFI typically presents with progressive insomnia, dysautonomia, and motor signs with rapid progression, while the fCJD phenotype manifests with cognitive decline and myoclonus. The critical clinical challenge lies in the pre-symptomatic phase: affected carriers remain asymptomatic for decades before rapid disease onset, making baseline biomarker establishment essential. Current research emphasizes identifying pre-symptomatic changes to define therapeutic intervention windows, as symptom onset signals extremely rapid neurodegeneration with survival typically under 18 months.

## Therapeutic Landscape

Therapeutic development for D178N focuses on targeting protein aggregation, with computational analysis identifying a high-probability aggregation hotspot at residues 248-252 (score: 0.83). The candidate peptide CP-PRNP-001 has been designed to specifically target this region, potentially interfering with pathogenic PrP^Sc formation. The therapeutic rationale centers on preventing conformational conversion and subsequent aggregation of the mutant protein. The 248-252 region represents a promising intervention point as it likely participates in the critical nucleation events that drive prion propagation. However, the therapeutic landscape remains largely experimental, with no approved disease-modifying treatments currently available. The challenge lies in developing blood-brain barrier-penetrant agents that can selectively stabilize PrP^C or prevent PrP^Sc accumulation without disrupting normal prion protein function in copper homeostasis and neuroprotective signaling.

## Research Directions

Critical knowledge gaps demand urgent investigation: (1) structural characterization of how D178N specifically destabilizes the native fold and promotes misfolding, leveraging AlphaFold predictions alongside experimental validation; (2) identification and validation of pre-symptomatic biomarkers in cerebrospinal fluid and blood that correlate with disease proximity in asymptomatic carriers; (3) natural history studies collecting longitudinal baseline data from mutation carriers to map the earliest detectable pathological changes; (4) validation of CP-PRNP-001 and related aggregation inhibitors in cellular and animal models of D178N-mediated prion disease; and (5) investigation of how codon 129 polymorphism mechanistically determines phenotypic divergence between FFI and fCJD. Additionally, exploring whether modulating PRNP's interactions with APP and HTT could provide therapeutic benefit warrants investigation, given the convergent pathways in neurodegenerative proteinopathies.

---

## Agent Findings

### Literature (1)
- **2026-05-23:** Only one paper directly addresses Fatal Familial Insomnia, which is specifically associated with the PRNP D178N mutation. The other papers discuss different PRNP mutations (V180I/M232R, G114V, T107I) or general prion research in animal models, making them less relevant to the specific D178N variant and its associated phenotypes.

### Clinical (1)
- **2026-05-19:** The PRNP D178N variant causes fatal familial insomnia (FFI) or familial Creutzfeldt-Jakob disease (fCJD) depending on the methionine/valine polymorphism at codon 129, making this baseline data collection critical for establishing pre-symptomatic biomarkers and disease progression patterns. This initial data will enable clinicians to identify the earliest detectable changes in carriers before symptom onset, potentially allowing for future therapeutic intervention windows and more precise prognostic counseling for affected families. The baseline measurements are essential for developing monitoring protocols since these prion diseases have rapid progression once symptoms appear, making early detection strategies crucial for patient management.

### Structural (1)
- **2026-05-20:** AlphaFold structure update: Baseline check: 1 structure(s) found

### Synthesis (1)
- **2026-05-20:** Synthesis of 1 findings (literature): The PRNP D178N variant continues to be primarily associated with Fatal Familial Insomnia (FFI), a de...

---

*Generated by [Clarity Protocol](https://clarityprotocol.io)*

**Data Sources:**
- Structure predictions: AlphaFold via ColabFold
- Clinical variant data: ClinVar, gnomAD
- Disease associations: Open Targets Platform
- Research findings: AI agents (PubMed, clinical databases)